ResMed Inc. which can be found using ticker (RMD) have now 10 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The target price High/Low ranges between 290 and 221 and has a mean target at $259.95. Given that the stocks previous close was at $218.50 this is indicating there is a potential upside of 19.0%. There is a 50 day moving average of $222.73 and the 200 moving average now moves to $219.74. The company has a market capitalization of 31.54B. The stock price for the company is currently is currently 214.65 USD
The potential market cap would be $37,521,717,414 based on the market consensus.
The company has a dividend yield of 2.05%. Other points of data to note are a P/E ratio of 36.76, revenue per share of 27.39 and a 12.06% return on assets.
ResMed Inc. is a holding company. The Company, through its subsidiaries, is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep-disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. It also offers software solutions for a variety of out-of-hospital care providers. The Company has two segments: Sleep and Respiratory Care and the Software-as-a-Service. Sleep apnea includes obstructive sleep apnea and other respiratory disorders that occur during sleep. Its cloud-based digital health applications, along with its devices, are designed to provide connected care to improve patient outcomes. The Company’s portfolio of products includes ventilation devices, diagnostic products, mask systems, headgear and other accessories, dental devices and cloud-based software informatics solutions.
